Pharma may duck overpriced Turkey acquisitions until Christmas 2012
This article was originally published in Scrip
Executive Summary
Perhaps anticipating interest from large pharma companies keen to expand their emerging market presence, companies in Turkey are currently too costly to be attractive acquisitions. But medicine price cuts imposed by the Turkish government may help to make Turkish firms more affordable by the end of the year.